Halozyme Therapeutics, Inc. (NASDAQ:HALO) Expands Delivery Platform, Poised For Near-Term Revenue Lift

Strong corporate moves and a growing royalty base position Halozyme for continued top-line momentum, while short-term technical indicators signal pressure that could temper near-term upside.

Recent News

On October 1, 2025 Halozyme announced a deal to acquire Elektrofi for up to $900 million, including $750 million upfront and $150 million in regulatory milestones, to add high-concentration Hypercon delivery technology. On November 6, 2025 Halozyme priced $650 million of 0% convertible senior notes due 2031 and $650 million of 0.875% convertible senior notes due 2032 as part of a larger financing plan. On November 12, 2025 Halozyme registered a higher Relative Strength rating and analyst commentary highlighted improved price performance following recent corporate developments.

Technical Analysis

ADX at 25.09 indicates a strengthening trend environment; directional indicators show DI+ at 22.46 with a peak-and-reversal, and DI- at 16.63 with a dip-and-reversal, which together suggest the trend strength currently supports downside momentum while longer-term trend integrity persists.

MACD sits at 0.40 below its signal line at 0.54 and shows a peak-and-reversal, a configuration that signals bearish momentum and increases the likelihood of further short-term price pressure relative to recent highs.

MRO reads positive at 1.58 with an increasing trajectory, indicating price presently trades above the model target and carries a modest probability of mean reversion toward intrinsic measures; that dynamic aligns with other short-term weakening indicators.

RSI at 51.68 with a peak-and-reversal indicates recent loss of upward momentum and leaves room for additional downward movement before reaching oversold conditions, supporting a near-term bias toward consolidation or pullback.

Price sits below several short-term trend measures: the 20-day average ($70.54), 12-day EMA ($69.92) and ichimoku Tenkan-sen ($70.31), while remaining above the 200-day average ($63.04). That arrangement favors mean reversion toward short-term averages while longer-term support near the 200-day average may limit deeper declines.

Bollinger band placement shows the close ($66.54) has slipped below the 1x lower band ($68.39) but remains above the 2x lower band ($66.25), a position that exhibits short-term downside extension without an extreme volatility breakout; the super trend upper at $72.83 serves as nearby resistance for any recovery attempt.

Volume at 1,864,847 trails 10-, 50- and 200-day averages, implying reduced conviction in recent moves and increasing the significance of any volume uptick that accompanies a directional shift.

 


Fundamental Analysis

Total revenue reported at $354,264,000 and net income at $175,225,000 reflect strong royalty-driven margins; gross margin stands at 84.41% and operating margin at 61.51%, while EBIT margin registers 63.02%. EBIT margin improved by 7.74% year-over-year and contracted by 1.94% quarter-over-quarter. The company reported GAAP diluted EPS of $1.43 versus an estimate of $1.39, producing an EPS surprise of 2.88%.

Liquidity measures show cash and short-term investments of $701,963,000 and cash of $419,665,000, with a cash ratio of 83.84% and quick ratio of 1.365, supporting near-term obligations despite a net debt position of $1,091,092,000 after borrowing. Interest coverage sits at 51.97x, indicating ample capacity to service interest even with elevated leverage metrics such as debt-to-equity at 299.80% and debt-to-EBITDA at 6.20x.

Cash flow metrics remain favorable: operating cash flow at $178,597,000, free cash flow at $175,567,000 and a cash flow margin of 44.92%. Free cash flow yield equals 2.21% and free cash flow grew 78.88% year-over-year while contracting QoQ. Free cash flow converts roughly 100% of net income into cash, supporting both buybacks and M&A activity.

Growth and efficiency show mixed signals: reported revenue growth sits at 8.76% while YoY revenue growth figure reads -65.48% in the provided metrics; return on equity measures 34.77% and return on assets 8.20%, and asset turnover remains low at 0.1657, consistent with a royalty-heavy business model that generates high margins on modest asset intensity.

Valuation multiples present elevated expectations: trailing P/E at 47.21x, forward P/E at 56.63x and enterprise multiple of 35.88. Price-to-book near 15.74 contrasts with industry peer mean and median book multiples, placing tangible-book comparisons above industry peer mean and median. WMDST values the stock as over-valued based on these multiples and the balance of cash generation against capital structure commitments.

MOST-RECENT QUARTERLY REPORT
REPORT PERIOD ENDING: 2025-09-30
REPORT DATE: 2025-11-03
NEXT REPORT DATE: 2026-02-02
CASH FLOW  Begin Period Cash Flow 61.9 M
 Operating Cash Flow 178.6 M
 Capital Expenditures -3.03 M
 Change In Working Capital -58.28 M
 Dividends Paid
 Cash Flow Delta 357.8 M
 End Period Cash Flow 419.7 M
 
INCOME STATEMENT REVENUE
 Total Revenue 354.3 M
 Forward Revenue 71.9 M
COSTS
 Cost Of Revenue 55.2 M
 Depreciation 2.7 M
 Depreciation and Amortization 20.4 M
 Research and Development 17.3 M
 Total Operating Expenses 136.3 M
PROFITABILITY
 Gross Profit 299.0 M
 EBITDA 243.7 M
 EBIT 223.3 M
 Operating Income 217.9 M
 Interest Income
 Interest Expense 4.3 M
 Net Interest Income -4.30 M
 Income Before Tax 219.0 M
 Tax Provision 43.7 M
 Tax Rate 20.2 %
 Net Income 175.2 M
 Net Income From Continuing Operations 175.2 M
EARNINGS
 EPS Estimate 1.39
 EPS Actual 1.43
 EPS Difference 0.04
 EPS Surprise 2.878 %
 Forward EPS 1.21
 
BALANCE SHEET ASSETS
 Total Assets 2.2 B
 Intangible Assets 765.4 M
 Net Tangible Assets -261.45 M
 Total Current Assets 1.3 B
 Cash and Short-Term Investments 702.0 M
 Cash 419.7 M
 Net Receivables 351.3 M
 Inventory 185.8 M
 Long-Term Investments 55.7 M
LIABILITIES
 Accounts Payable 15.4 M
 Short-Term Debt 710.7 M
 Total Current Liabilities 837.2 M
 Net Debt 1.1 B
 Total Debt 1.5 B
 Total Liabilities 1.7 B
EQUITY
 Total Equity 503.9 M
 Retained Earnings 502.1 M
VALUATION & PER-SHARE METRICS EQUITY & PER-SHARE METRICS
 Book Value Per-Share 4.29
 Shares Outstanding 117.523 M
 Revenue Per-Share 3.01
VALUATION
 Market Capitalization 7.9 B
 Enterprise Value 8.7 B
 Enterprise Multiple 35.877
Enterprise Multiple QoQ -0.803 %
Enterprise Multiple YoY -12.585 %
Enterprise Multiple IPRWA high: 52.77
HALO: 35.877
median: 24.843
mean: 4.591
low: -79.113
 EV/R 24.677
CAPITAL STRUCTURE
 Asset To Equity 4.408
 Asset To Liability 1.293
 Debt To Capital 0.75
 Debt To Assets 0.68
Debt To Assets QoQ -7.432 %
Debt To Assets YoY -4.229 %
Debt To Assets IPRWA high: 1.045
HALO: 0.68
mean: 0.21
median: 0.073
low: 0.0
 Debt To Equity 2.998
Debt To Equity QoQ -33.895 %
Debt To Equity YoY -9.769 %
Debt To Equity IPRWA HALO: 2.998
high: 1.395
mean: 0.193
median: 0.09
low: -0.869
PRICE-BASED VALUATION
 Price To Book (P/B) 15.744
Price To Book QoQ -28.74 %
Price To Book YoY 2.381 %
Price To Book IPRWA high: 17.968
HALO: 15.744
mean: 6.887
median: 5.638
low: -8.555
 Price To Earnings (P/E) 47.207
Price To Earnings QoQ 10.622 %
Price To Earnings YoY 9.531 %
Price To Earnings IPRWA high: 56.753
HALO: 47.207
mean: -4.369
median: -12.694
low: -93.179
 PE/G Ratio 6.278
 Price To Sales (P/S) 22.394
Price To Sales QoQ -0.779 %
Price To Sales YoY -6.683 %
Price To Sales IPRWA high: 1129.647
mean: 73.955
median: 26.34
HALO: 22.394
low: 0.466
FORWARD MULTIPLES
Forward P/E 56.626
Forward PE/G 7.531
Forward P/S 110.378
EFFICIENCY OPERATIONAL
 Operating Leverage 0.759
ASSET & SALES
 Asset Turnover Ratio 0.166
Asset Turnover Ratio QoQ 8.137 %
Asset Turnover Ratio YoY 16.761 %
Asset Turnover Ratio IPRWA high: 0.438
HALO: 0.166
mean: 0.116
median: 0.107
low: 0.0
 Receivables Turnover 1.052
Receivables Turnover Ratio QoQ 2.253 %
Receivables Turnover Ratio YoY -9.974 %
Receivables Turnover Ratio IPRWA high: 6.279
mean: 1.457
median: 1.412
HALO: 1.052
low: 0.006
 Inventory Turnover 0.301
Inventory Turnover Ratio QoQ 12.373 %
Inventory Turnover Ratio YoY -11.535 %
Inventory Turnover Ratio IPRWA high: 2.722
mean: 0.602
median: 0.37
HALO: 0.301
low: -0.015
 Days Sales Outstanding (DSO) 86.774
CASH CYCLE
 Cash Conversion Cycle Days (CCC) 414.748
Cash Conversion Cycle Days QoQ 9.524 %
Cash Conversion Cycle Days YoY 8.869 %
Cash Conversion Cycle Days IPRWA high: 1241.621
HALO: 414.748
median: 189.366
mean: 184.748
low: -1809.09
CAPITAL DEPLOYMENT
 Cash Conversion Ratio 0.721
 CapEx To Revenue -0.009
 CapEx To Depreciation -1.14
 
CAPITAL, LIQUIDITY & COVERAGE CAPITAL STRUCTURE
 Total Capital 1.3 B
 Net Invested Capital 2.0 B
 Invested Capital 2.0 B
 Net Tangible Assets -261.45 M
 Net Working Capital 491.5 M
LIQUIDITY
 Cash Ratio 0.838
 Current Ratio 1.587
Current Ratio QoQ -81.017 %
Current Ratio YoY -84.676 %
Current Ratio IPRWA high: 25.502
mean: 4.402
median: 3.195
HALO: 1.587
low: 0.02
 Quick Ratio 1.365
Quick Ratio QoQ -80.522 %
Quick Ratio YoY -85.079 %
Quick Ratio IPRWA high: 13.391
mean: 2.807
median: 2.481
HALO: 1.365
low: 0.02
COVERAGE & LEVERAGE
 Debt To EBITDA 6.2
 Cost Of Debt 0.227 %
 Interest Coverage Ratio 51.968
Interest Coverage Ratio QoQ 9.084 %
Interest Coverage Ratio YoY 38.564 %
Interest Coverage Ratio IPRWA high: 815.709
HALO: 51.968
mean: 40.044
median: 4.2
low: -1538.4
 Operating Cash Flow Ratio 0.19
TIMING / LIQUIDITY
 Days Payables Outstanding (DPO) 33.512
DIVIDENDS
 Dividend Coverage Ratio
 Dividend Payout Ratio
 Dividend Rate
 Dividend Yield
PERFORMANCE GROWTH
 Asset Growth Rate 8.147 %
 Revenue Growth 8.764 %
Revenue Growth QoQ -61.858 %
Revenue Growth YoY -65.477 %
Revenue Growth IPRWA high: 301.849 %
HALO: 8.764 %
mean: 8.031 %
median: 4.118 %
low: -259.856 %
 Earnings Growth 7.519 %
Earnings Growth QoQ -62.064 %
Earnings Growth YoY -80.993 %
Earnings Growth IPRWA high: 162.5 %
HALO: 7.519 %
median: -6.452 %
mean: -13.336 %
low: -198.545 %
MARGINS
 Gross Margin 84.407 %
Gross Margin QoQ -1.586 %
Gross Margin YoY 1.743 %
Gross Margin IPRWA high: 105.39 %
HALO: 84.407 %
median: 83.077 %
mean: 79.758 %
low: -35.147 %
 EBIT Margin 63.019 %
EBIT Margin QoQ -1.943 %
EBIT Margin YoY 7.743 %
EBIT Margin IPRWA high: 3270.865 %
HALO: 63.019 %
median: 34.344 %
mean: -114.698 %
low: -8139.786 %
 Return On Sales (ROS) 61.514 %
Return On Sales QoQ -1.027 %
Return On Sales YoY 5.17 %
Return On Sales IPRWA high: 573.037 %
HALO: 61.514 %
median: 26.151 %
mean: -178.194 %
low: -8613.378 %
CASH FLOW
 Free Cash Flow (FCF) 175.6 M
 Free Cash Flow Yield 2.213 %
Free Cash Flow Yield QoQ 65.768 %
Free Cash Flow Yield YoY 35.269 %
Free Cash Flow Yield IPRWA high: 30.655 %
HALO: 2.213 %
median: 0.686 %
mean: 0.295 %
low: -57.887 %
 Free Cash Growth 78.88 %
Free Cash Growth QoQ -319.33 %
Free Cash Growth YoY -30.79 %
Free Cash Growth IPRWA high: 190.123 %
HALO: 78.88 %
mean: 27.411 %
median: 21.696 %
low: -198.468 %
 Free Cash To Net Income 1.002
 Cash Flow Margin 44.916 %
 Cash Flow To Earnings 0.908
VALUE & RETURNS
 Economic Value Added 0.04
 Return On Assets (ROA) 8.197 %
Return On Assets QoQ 5.482 %
Return On Assets YoY 22.27 %
Return On Assets IPRWA high: 30.5 %
HALO: 8.197 %
median: -0.134 %
mean: -2.312 %
low: -66.968 %
 Return On Capital Employed (ROCE) 16.131 %
 Return On Equity (ROE) 0.348
Return On Equity QoQ -29.943 %
Return On Equity YoY 14.895 %
Return On Equity IPRWA high: 0.948
HALO: 0.348
median: -0.002
mean: -0.008
low: -1.385
 DuPont ROE 41.886 %
 Return On Invested Capital (ROIC) 8.843 %
Return On Invested Capital QoQ -3.45 %
Return On Invested Capital YoY -47.325 %
Return On Invested Capital IPRWA high: 31.965 %
HALO: 8.843 %
median: 4.232 %
mean: -0.169 %
low: -73.241 %

Six-Week Outlook

Short-term technical indicators favor consolidation or modest downside pressure while corporate catalysts—an acquisition that expands high-concentration delivery capabilities and recent convertible note financings—sustain upside potential at a fundamental level. If MACD remains below its signal and DI+ continues its peak-and-reversal, expect continued short-term weakness into moving-average support near the 200-day average; a decisive MACD cross above the signal or a DI+ dip-and-reversal would signal re-acceleration of bullish momentum. Monitor volume for conviction behind any directional change and track cash and debt developments tied to the Elektrofi acquisition and convertible note activity for material shifts in capital structure or guidance.

About Halozyme Therapeutics, Inc.

Halozyme Therapeutics, Inc. (NASDAQ:HALO) develops advanced biopharmaceutical solutions to enhance the delivery of injectable therapeutics. Based in San Diego, California, Halozyme employs its proprietary enzyme technology platform, notably the recombinant human hyaluronidase enzyme (rHuPH20), to facilitate subcutaneous administration of biologics and monoclonal antibodies. This technology improves the absorption and dispersion of injected drugs, optimizing therapeutic efficacy. The company’s product line includes Hylenex recombinant, designed to enhance drug delivery, and a variety of treatments targeting conditions such as HIV, multiple sclerosis, and cancer. Noteworthy products include Herceptin Hylecta and Phesgo for breast cancer, and DARZALEX for multiple myeloma. Halozyme also provides solutions for primary immunodeficiency disorders with HYQVIA and offers treatments for severe autoimmune diseases and adrenal crisis rescue. Halozyme collaborates with leading pharmaceutical companies globally to integrate its technology into diverse therapeutic applications, aiming to improve patient outcomes. By transforming drug delivery methods, Halozyme contributes significantly to the field of injectable therapeutics, advancing healthcare solutions both in the United States and internationally.



© 2025 WMDST — The World’s Most Dangerous Swing Trader. All rights reserved.